Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile ALK F1174L
Therapy Ceritinib + TNO155
Indication/Tumor Type neuroblastoma
Response Type sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ALK F1174L neuroblastoma sensitive Ceritinib + TNO155 Preclinical - Cell line xenograft Actionable In a preclinical study, treatment with the combination of TNO155 and Zykadia (ceritinib) resulted in enhanced inhibition of downstream signaling and invasion and synergistically decreased viability of neuroblastoma cell lines harboring ALK F1174L in culture and led to significantly decreased tumor growth in a cell line xenograft model compared to either agent alone (PMID: 38032104). 38032104
PubMed Id Reference Title Details
(38032104) SHP2 inhibition with TNO155 increases efficacy and overcomes resistance of ALK inhibitors in neuroblastoma. Full reference...